Defence Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is July - June.

Millions CAD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-3.62	-3.52	-13.19	-6.76	-7.34	-2.86
Depreciation & Amortization	0.07	0.07	0.09	0.01	-	-
Stock-Based Compensation	0.84	0.79	5.84	0.3	0.37	0.61
Other Operating Activities	0.21	0.24	0.4	0.16	-	-
Change in Accounts Receivable	-0.19	-0.1	0.05	-0.12	0.04	-
Change in Accounts Payable	-1.52	-0.91	2.1	-0.89	0.98	0.07
Change in Other Net Operating Assets	0	0.03	0.43	-0.35	-0.1	-0.11
Operating Cash Flow	-4.21	-3.4	-4.29	-7.66	-6.04	-2.29
Capital Expenditures	-0.02	-	-0.2	-0.07	-	-
Sale of Property, Plant & Equipment	0	0	-	-	-	-
Investing Cash Flow	-0.02	0	-0.2	-0.07	-	-
Short-Term Debt Issued	-	0.02	0.05	-	-	-
Long-Term Debt Issued	-	-	-	2.36	-	-
Total Debt Issued	2	0.02	0.05	2.36	-	-
Short-Term Debt Repaid	-	-0.07	-	-	-	-
Long-Term Debt Repaid	-	-0.12	-0.06	-	-	-
Total Debt Repaid	-0.17	-0.18	-0.06	-	-	-
Net Debt Issued (Repaid)	1.83	-0.17	-0.01	2.36	-	-
Issuance of Common Stock	5.02	5.02	1.89	8.25	1.1	2.76
Other Financing Activities	-0.44	-0.28	-0.12	-0.59	-	3.12
Financing Cash Flow	6.41	4.57	1.76	10.01	1.1	5.88
Foreign Exchange Rate Adjustments	0.01	0	-	-	-	-
Net Cash Flow	2.19	1.18	-2.74	2.29	-4.95	3.59
Free Cash Flow	-4.23	-3.4	-4.49	-7.72	-6.04	-2.29
Free Cash Flow Per Share	-0.08	-0.07	-0.10	-0.20	-0.17	-0.09
Cash Interest Paid	0	0	0.04	0.01	-	-
Levered Free Cash Flow	-3.01	-2.31	0.09	-5.34	-3.25	-1.2
Unlevered Free Cash Flow	-2.87	-2.11	0.34	-5.18	-3.25	-1.2
Change in Working Capital	-1.71	-0.99	2.58	-1.36	0.93	-0.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.